Clinical Trial Update: Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis [Phase 2]

View source ↗

Summary

Phase 2 study of TL-895 in patients with myelofibrosis or indolent systemic mastocytosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Systemic Mastocytosis
• Myelofibrosis

Drugs mentioned

• TL-895

Snippet

Sponsor: Telios Pharma, Inc. | Conditions: Myelofibrosis, Indolent Systemic Mastocytosis | Phase 2 | Status: RECRUITING